Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...

Oprah Winfrey is opening up about how using weight-loss drugs (like Ozempic, Wegovy and Mounjaro) has impacted the way she ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

When it comes to medically assisted weight loss, there’s two main schools of thought: either weight loss drugs, like the ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...